AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly Cash from Investing Activities of -$21.7 million for Q1 2026, down 96.6% year-over-year from -$636.0 million in Q1 2025, and down 96.6% quarter-over-quarter from -$11.0 million in Q1 2025.
Analysis
AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026) Analysis & Trends
AtaiBeckley has reported Cash from Investing Activities for 6 years, with the latest figure at -$67.6 million in Q3 2025.
- Quarterly Cash from Investing Activities fell 371.95% year-over-year to -$67.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$62.2 million (down 220.15% YoY) and the FY2024 annual result came in at $59.2 million, up 211.03% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$21.7 million, down from -$11.0 million in the prior quarter.
- The five-year high for Cash from Investing Activities was -$11.0 million in Q1 2025, with the low at -$21.7 million in Q1 2026.
- A 5-year average of -$12.2 million and a median of -$823000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 10857.33% in 2022, down 5670.92% in 2022.
- Over 5 years, Cash from Investing Activities stood at -$48.6 million in 2021, then jumped by 264.6% to $80.1 million in 2022, then slumped by 101.03% to -$823000.0 in 2023, then surged by 897.08% to $6.6 million in 2024, then plunged by 1129.77% to -$67.6 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$67.6 million, $9.8 million, and -$11.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - | -67.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 158.59 Mn |
| Mar 31, 2026 | -21.65 Mn |
| Sep 30, 2025 | -67.55 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Sep 30, 2024 | 24.84 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Dec 31, 2023 | -823,000.00 |
| Sep 30, 2023 | -46.49 Mn |
| Jun 30, 2023 | -22.01 Mn |
| Mar 31, 2023 | 16.02 Mn |
| Dec 31, 2022 | 80.05 Mn |
| Sep 30, 2022 | 66.05 Mn |
| Jun 30, 2022 | -18.21 Mn |
| Mar 31, 2022 | -214.74 Mn |
| Dec 31, 2021 | -48.63 Mn |